Markus August Seeliger

Dr. Markus August Seeliger

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2011 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YSYibing Shan
Yibing Shan
EKEric T. Kim
Eric T. Kim
MEMichael P. Eastwood
Michael P. Eastwood
RDRon O. Dror
Ron O. Dror
MSMarkus August Seeliger
Markus August Seeliger
DSDavid E. Shaw
David E. Shaw

14 September 2008 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
MAMohammad Azam
Mohammad Azam
MSMarkus August Seeliger
Markus August Seeliger
NGNathanael S Gray
Nathanael S Gray
JKJohn Kuriyan
John Kuriyan
GDGeorge Q Daley
George Q Daley
Substitution of the active site gatekeeper residue in the BCR-ABL oncoprotein and related kinases is a common mechanism of imanitib resistance but has also been observed in drug-naïve patients. New work suggests that this residue stabilizes a hydrophobic spine that links the N and C kinase lobes, promoting the active conformation, and that adverse mutations at the gatekeeper residue further stabilize the spine. Disruption of the spine would be an attractive new goal in drug development. Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-α and -β, and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells. Structural analysis reveals that a network of hydrophobic interactions—the hydrophobic spine—characteristic of the active kinase conformation is stabilized by the gatekeeper substitution. Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase. Furthermore, a small-molecule inhibitor that maximizes complementarity with the dismantled spine (compound 14) inhibits the gatekeeper mutation of BCR-ABL-T315I. These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.

1 April 2011 in Molecular Cell
Verified
Journal Article
Closed access
NJNatalia Jura
Natalia Jura
XZXuewu Zhang
Xuewu Zhang
NENicholas F. Endres
Nicholas F. Endres
MSMarkus August Seeliger
Markus August Seeliger
TSThomas Schindler
Thomas Schindler
JKJohn Kuriyan
John Kuriyan

27 March 2011 in Nature
Verified
Journal Article
Open access
PDF file
BMBen Montpetit
Ben Montpetit
NTNathan D. Thomsen
Nathan D. Thomsen
KHKara J. Helmke
Kara J. Helmke
MSMarkus August Seeliger
Markus August Seeliger
JBJames M Berger
James M Berger
KWKarsten Weis
Karsten Weis
As mRNA-protein complexes are exported from the nucleus to the cytoplasm, they pass through the nuclear pore complex (NPC). Dbp5, an RNA helicase associated with the NPC through the Nup159 subunit, remodels such mRNA-protein complexes. Montpetit et al. present the structure of Dbp5 bound to Gle1 and the small-molecule activator InsP6, with and without Nup159 and RNA. Similarities to the structure of the translation initiation complex, eIF4G–eIF4A suggests that Gle1InsP6 activates Dbp5 by relieving an autoinhibitory mechanism, by promoting release of RNA, and (with Nup159) by stabilizing a conformation that cannot bind RNA. Superfamily 1 and superfamily 2 RNA helicases are ubiquitous messenger-RNA–protein complex (mRNP) remodelling enzymes that have critical roles in all aspects of RNA metabolism1,2. The superfamily 2 DEAD-box ATPase Dbp5 (human DDX19) functions in mRNA export and is thought to remodel mRNPs at the nuclear pore complex (NPC)3,4,5,6,7,8. Dbp5 is localized to the NPC via an interaction with Nup159 (NUP214 in vertebrates)3,4,5,8,9 and is locally activated there by Gle1 together with the small-molecule inositol hexakisphosphate (InsP6)10,11. Local activation of Dbp5 at the NPC by Gle1 is essential for mRNA export in vivo10,12; however, the mechanistic role of Dbp5 in mRNP export is poorly understood and it is not known how Gle1InsP6 and Nup159 regulate the activity of Dbp5. Here we report, from yeast, structures of Dbp5 in complex with Gle1InsP6, Nup159/Gle1InsP6 and RNA. These structures reveal that InsP6 functions as a small-molecule tether for the Gle1–Dbp5 interaction. Surprisingly, the Gle1InsP6–Dbp5 complex is structurally similar to another DEAD-box ATPase complex essential for translation initiation, eIF4G–eIF4A, and we demonstrate that Gle1InsP6 and eIF4G both activate their DEAD-box partner by stimulating RNA release. Furthermore, Gle1InsP6 relieves Dbp5 autoregulation and cooperates with Nup159 in stabilizing an open Dbp5 intermediate that precludes RNA binding. These findings explain how Gle1InsP6, Nup159 and Dbp5 collaborate in mRNA export and provide a general mechanism for DEAD-box ATPase regulation by Gle1/eIF4G-like activators.

6 January 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YSYibing Shan
Yibing Shan
MSMarkus August Seeliger
Markus August Seeliger
MEMichael P. Eastwood
Michael P. Eastwood
FFFilipp Frank
Filipp Frank
HXHuafeng Xu
Huafeng Xu
DSDavid E. Shaw
David E. Shaw
In many protein kinases, a characteristic conformational change (the “DFG flip”) connects catalytically active and inactive conformations. Many kinase inhibitors—including the cancer drug imatinib—selectively target a specific DFG conformation, but the function and mechanism of the flip remain unclear. Using long molecular dynamics simulations of the Abl kinase, we visualized the DFG flip in atomic-level detail and formulated an energetic model predicting that protonation of the DFG aspartate controls the flip. Consistent with our model's predictions, we demonstrated experimentally that the kinetics of imatinib binding to Abl kinase have a pH dependence that disappears when the DFG aspartate is mutated. Our model suggests a possible explanation for the high degree of conservation of the DFG motif: that the flip, modulated by electrostatic changes inherent to the catalytic cycle, allows the kinase to access flexible conformations facilitating nucleotide binding and release.

15 January 2006 in Cancer Research
Verified
Journal Article
Open access
PDF file
MYMatthew A. Young
Matthew A. Young
NSNeil P. Shah
Neil P. Shah
LCLuke H. Chao
Luke H. Chao
MSMarkus August Seeliger
Markus August Seeliger
ZMZdravko V. Milanov
Zdravko V. Milanov
JKJohn Kuriyan
John Kuriyan
We present a high-resolution (2.0 Å) crystal structure of the catalytic domain of a mutant form of the Abl tyrosine kinase (H396P; Abl-1a numbering) that is resistant to the Abl inhibitor imatinib. The structure is determined in complex with the small-molecule inhibitor VX-680 (Vertex Pharmaceuticals, Cambridge, MA), which blocks the activity of various imatinib-resistant mutant forms of Abl, including one (T315I) that is resistant to both imatinib and BMS-354825 (dasatinib), a dual Src/Abl inhibitor that seems to be clinically effective against all other imatinib-resistant forms of BCR-Abl. VX-680 is shown to have significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. The Abl kinase domain bound to VX-680 is not phosphorylated on the activation loop in the crystal structure but is nevertheless in an active conformation, previously unobserved for Abl and inconsistent with the binding of imatinib. The adoption of an active conformation is most likely the result of synergy between the His396Pro mutation, which destabilizes the inactive conformation required for imatinib binding, and the binding of VX-680, which favors the active conformation through hydrogen bonding and steric effects. VX-680 is bound to Abl in a mode that accommodates the substitution of isoleucine for threonine at residue 315 (the “gatekeeper” position). The avoidance of the innermost cavity of the Abl kinase domain by VX-680 and the specific recognition of the active conformation explain the effectiveness of this compound against mutant forms of BCR-Abl, including those with mutations at the gatekeeper position. (Cancer Res 2006; 66(2): 1007-14)